MedPath

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

Not Applicable
Withdrawn
Conditions
Cardiac Event Risk
Interventions
Registration Number
NCT01330654
Lead Sponsor
University of California, San Francisco
Brief Summary

Beta blockers have been shown to decrease the risk of intraoperative cardiac events in patients at high cardiac risk. However, they have also been associated with side effects (for instance, stroke.) The role of beta blockers in patients at intermediate cardiac risk undergoing surgery is controversial. Heart rate variability is a way of evaluating the cardiac function of a patient. Decreased heart rate variability is associated with early cardiac death in patients with congestive heart failure (CHF) and after a heart attack. It has been shown to transiently decrease in patients in hemorrhagic shock after trauma and returns to normal after resuscitation in trauma and burn patients. The investigators hypothesize that beta blockers will maintain pre operative heart rate variability in patients with intermediate risk of cardiac events during operative intervention with laparoscopic surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • age 40-75 years old

  • intermediate risk of adverse cardiac events:

    • renal insufficiency (CrCl < 60)

    • diabetes mellitus

    • two of the following:

      • age > 50
      • obesity
      • hypertension
      • hyperlipidemia
      • hypercholesterolemia
      • prior stroke
    • undergoing an elective laparoscopic abdominal surgery less than three hours:

      • cholecystectomy
      • ventral hernia repair
      • umbilical hernia repair
      • gastric bypass or gastric banding
Exclusion Criteria
  • currently taking a beta blocker

  • prior heart attack

  • rhythm other than sinus on ECG

  • contraindication to beta blockers:

    • decompensated CHF
    • severe valvular disease
    • asthma
    • COPD
    • hypersensitivity to beta blockers
    • heart rate < 60
  • currently taking a calcium channel blocker

  • urgent or emergent surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Beta blockermetoprololThese patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
Primary Outcome Measures
NameTimeMethod
Heart Rate Variability2 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Community Regional Medical Center

🇺🇸

Fresno, California, United States

© Copyright 2025. All Rights Reserved by MedPath